Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile?
- 1 January 1993
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 32 (6) , 411-418
- https://doi.org/10.1007/bf00685883
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.Archives of Disease in Childhood, 1991
- Fat Body Mass and Pharmacokinetics of Oral 6-Mercaptopurine in Children with Acute Lymphoblastic LeukemiaTherapeutic Drug Monitoring, 1991
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990
- Is Dose Normalization to Weight or Body Surface Area Useful in Adults?JNCI Journal of the National Cancer Institute, 1990
- 6-Mercaptopurine Plasma Levels in Children with Acute Lymphoblastic LeukemiaTherapeutic Drug Monitoring, 1989
- Interspecific Scaling of Toxicity DataRisk Analysis, 1988
- Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelinesEuropean Journal of Cancer and Clinical Oncology, 1987
- Dosage Regimen Design for Pharmaceutical Studies Conducted in AnimalsJournal of Pharmaceutical Sciences, 1986
- A distribution must be made between the ontogeny the phylogeny of metabolism in order to understand the mass exponent of energy metabolismRespiration Physiology, 1984
- Comparative Metabolism of Tritiated Water by MammalsJournal of Cellular and Comparative Physiology, 1962